OrthoPediatrics Corp.
KIDS Healthcare Medical Devices
OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.4%, EPS was flat, free cash flow grew 77.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow KIDS
OrthoPediatrics Corp. (KIDS) Piotroski F-score
OrthoPediatrics Corp.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 1.00 |
| FY2024 | 3 | 1.00 |
| FY2023 | 2 | (3.00) |
| FY2022 | 5 | 1.00 |
| FY2021 | 4 | 1.00 |
| FY2020 | 3 | 0.00 |
| FY2019 | 3 | 0.00 |
| FY2018 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (8.08%) | (8.29%) | Fail | 0 |
| Positive operating cash flow | (4.85m) | (27.05m) | Fail | 0 |
| Rising return on assets | (8.08%) | (8.29%) | Pass | 1 |
| Cash flow above net income | 34.80m | 10.77m | Pass | 1 |
| Falling long-term leverage | 0.20 | 0.16 | Fail | 0 |
| Rising current ratio | 5.55 | 6.98 | Fail | 0 |
| No new shares issued | 23,459,000 | 23,078,000 | Fail | 0 |
| Rising gross margin | 73.05% | 72.58% | Pass | 1 |
| Rising asset turnover | 0.48 | 0.45 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 8 |
| DCTH Delcath Systems, Inc. compare | 7 |
| BWAY Brainsway Ltd. Sponsored ADR compare | 6 |
| MASS 908 Devices Inc. compare | 5 |
| SGHT Sight Sciences, Inc. compare | 5 |
| SSII SS Innovations International, Inc. compare | 5 |
| KIDS OrthoPediatrics Corp. | 4 |
| CTKB Cytek Biosciences, Inc. compare | 4 |
| PACB Pacific Biosciences of California, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover